ISPOR Bernie O'Brien New Investigator Award

Anthony Newall

Anthony Newall, PhD, MPH, BSc, Associate Professor, UNSW Australia, School of Public Health and Community Medicine, The University of New South Wales, Sydney, NSW Australia

About ISPOR Bernie J. O’Brien New Investigator Award

Description:
The ISPOR Bernie O'Brien New Investigator Award was established in 2004 to honor the long-standing commitment of Bernie J. O'Brien, PhD to training and mentoring new scientists in the fields of outcomes research and pharmacoeconomics.

Criteria:
The recipient of the ISPOR Bernie O'Brien New Investigator Award is selected by the O'Brien New Investigator Award Committee. The recipient shall be a member of ISPOR on the date of nomination and be nominated by an individual who has been an ISPOR member in good standing for at least two consecutive years prior to the date of nomination. Evidence of exceptional promise shall be assessed by evaluating the nominee's emerging body of technical and scholarly work in the fields of pharmacoeconomics and outcomes research. The emerging body of work may include research publications, technical reports and papers, books and book chapters, and other scholarly activities that establish the importance of the nominee's early contributions. The nominees shall be no more than 7 years from the receipt of their last degree in outcomes research or related field and no more than 10 years from their first publication in outcomes research or related field.

Selection Process:
A call for nominations from the membership and the award selection criteria will be are published in November-December Value & Outcomes Spotlight. The New Investigator Committee Core Group meets via teleconference in March to discuss each of the nominees and select the nominee who best meets the criteria. The nominee is then forwarded to the Board of Directors for final approval.

Nature of the Award:
The Award will be known as "ISPOR Bernie J. O'Brien New Investigator Award."

The Award will be presented at the ISPOR Annual International Meeting or the Annual European Congress each year.

The Award consists of a plaque, complimentary meeting registration, an unrestricted research grant of US$5,000.00 and up to US$1,500.00 for travel expenses.

Timeline & Procedures: Following is the selection process timeline:

November/December:

» A Call for Nominations is published in Value & Outcomes Spotlight, December 15 issue.

January:

» An email message is sent to all Award Committee members requesting nominees who have advanced in the field.
» An email message will be sent to all ISPOR membership soliciting nominations

February:

» A second email message is sent to all ISPOR membership reminding them of the February 15 deadline for the nominations

March:

» The New Investigator Award Committee Core Group meets via teleconference to discuss and evaluate nominations.
» The Awardee, is sent to the Board of Directors for final approval. The Chair of the Award Committee informs the recipient. A letter from ISPOR President is sent to the recipient informing them of their selection and inviting them to attend the Annual International Meeting or European Congress to receive their award.

Nominations for the Bernie J. O'Brien New Investigator Award require a letter of support for the nominee and a current edition of the nominee's CV, and should be sent to: awards@ispor.org.

RECEIPIENTS OF THE ISPOR O'BRIEN NEW INVESTIGATOR AWARD

James D. Chambers

James D. Chambers, PhD, MPharm, MSc
Assistant Professor, Tufts Medical Center, Boston, MA, USA


James D. Chambers, PhD, MPharm, MSc, is an investigator at the Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, and an assistant professor of medicine at Tufts University in Boston, MA. James received his MPharm degree from Queens University in Belfast and previously worked as a pharmacist in the UK and Ireland. He also obtained an MSc from the University of York and PhD from Brunel University. James' research interests include examining the factors that influence coverage policy for medical technology, pharmaceutical innovation, and the use and potential value of cost-effectiveness analysis in the US health care system.

Anthony Newall
Anthony Newall, PhD


Dr. Newall is an Associate Professor in Health Economics at The School of Public Health and Community Medicine, UNSW Australia. He is also an Honorary Fellow at the Australian National Centre for Immunisation Research and Surveillance. He completed his MPH (Hons) and PhD at the University of Sydney on the cost-effectiveness of vaccination programs.

His main research area is the economic evaluation of infectious disease prevention strategies, as well as the statistical and epidemiological analyses that inform these evaluations. He has over 40 peer-reviewed publications on a range of vaccine preventable diseases, including the epidemiology and cost-effectiveness of prevention strategies for influenza (seasonal and pandemic), pneumococcal disease, rotavirus, and human papillomavirus.

He has been appointed to the World Health Organization Roster of Experts in the area of Health Economics and has been a visiting scholar at the National Institutes of Health. He has received several awards for his research and public health impact, including the prestigious Aileen Plant Memorial Prize and the Dean's Rising Star Award from the Faculty of Medicine, UNSW.

Anupam B. Jena, MD, PhD
Anupam B. Jena, MD, PhD
Assistant Professor, Harvard Health Care Policy, Harvard Medical School, Boston, MA, USA


Dr. Jena is an Assistant Professor of health care policy and medicine at Harvard Medical School and an internist at Massachusetts General Hospital. Dr. Jena is also a Faculty Research Fellow at the National Bureau of Economic Research. Dr. Jena's research involves several areas of health economics and policy including the economics of medical innovation and cost-effectiveness, the economics of physician behavior, medical malpractice, and productivity in health care. Dr. Jena graduated Phi Beta Kappa from the Massachusetts Institute of Technology and received his MD and PhD in Economics from the University of Chicago. He completed his residency in internal medicine at Massachusetts General Hospital. He is a recipient of the 2007 Eugene Garfield award from Research America for the best paper on the economic impact of medical technology. In 2013, he was the recipient of the NIH Director's Early Independence Award, a 5-year award given to 10-15 junior scientists nationally who show exceptional promise to conduct cross-cutting biomedical and behavioral science research.

Josh J. Carlson, MPH, PhD
Josh J. Carlson, MPH, PhD

Dr. Carlson is an Assistant Professor in the Pharmaceutical Outcomes Research and Policy Program at the University of Washington and an affiliate faculty member at the Fred Hutchinson Cancer Research Center.  He graduated with his PhD from the Institute for Public Health Genetics in the School of Public Health and Community Medicine at the University of Washington in 2007 and conducted his postdoctoral training in pharmacoeconomics at the University of Washington from 2007-2009. Dr. Carlson's current research interests and work to date has primarily focused on the intersection of three areas: 1) genomics and emerging technologies in the field of personalized medicine, 2) uncertainty both in our decision-making processes and as the concept applies to the application of medical technologies in "real world" settings (i.e. outside of clinical trials) including comparative effectiveness research, and 3) economic and policy options to address these uncertainties as we seek to improve our healthcare system and the health of our population.

Jennifer M. Polinski, ScD, MPH, MS
Jennifer M. Polinski, ScD, MPH, MS

Jennifer M. Polinski, ScD, MPH, MS (MPH, Health Education, Emory University; MS and ScD, Epidemiology, Harvard School of Public Health) is an epidemiologist and health services researcher in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital in Boston, MA.  She holds faculty appointments at Harvard Medical School and Harvard School of Public Health, where she teaches a course in epidemiologic methods applied to health services research.  Dr. Polinski’s research interests focus on the management and treatment of chronic disease, patient and physician education, and the impact of health interventions and health policy changes on elderly populations.  She has a special interest in government-funded health care programs.  Her recent work examined changes in Medicare beneficiaries’ drug utilization and health outcomes following the inception of the Medicare Part D program.  Current projects include identifying predictors of type 2 diabetes treatment progression, developing tools to improve primary medication adherence, and studying methods for causal inference in comparative effectiveness studies. 

Joanne LaFleur, PharmD, MSPH
Joanne LaFleur, PharmD, MSPH

Joanne LaFleur, PharmD, MSPH, is Assistant Professor in the Department of Pharmacotherapy within the University of Utah College of pharmacy. She has a joint appointment as a researcher in the Salt Lake City Veterans Affairs Informatics, Decision Enhancement, and Surveillance (IDEAS) center, where she focuses on applying the tools of health economics, biomedical informatics, and pharmacoepidemiology to outcomes research. She received her PharmD degree from the University of Utah in 2003 and went on to complete a Fellowship in Pharmacoeconomics and Outcomes Research and a Master’s degree in Public Health in 2005, both at the University of Utah. She spent 4 years as faculty on the research track, and recently changed tracks to join the tenure track faculty. The focus of her CDA, entitled “Knowledge engineering for decision support in osteoporosis,” is on the development of clinical decision support tools for osteoporotic fracture prevention.

Lesley-Tilson-2011.jpg
Lesley Tilson PhD
Lesley Tilson PhD, is currently the Chief I Pharmacist at the National Centre for Pharmacoeconomics (NCPE) in Ireland. She received her PhD in Pharmacoeconomics from Trinity College Dublin in 2005. Prior to joining the NCPE, she worked as a Clinical Pharmacist in the Oxford Radcliffe NHS Trust in the UK and in St James’s University Teaching Hospital in Dublin. Her research interests include methodological aspects of conducting economic evaluations and European pharmaceutical pricing and reimbursement strategies. She has extensive experience in conducting economic evaluations of new drugs, vaccination programmes and interventions for the control and prevention of cancer. Dr. Tilson led the team that investigated the cost-effectiveness of cervical cancer vaccination in the Irish healthcare setting. She also played a leading role in the cost-effectiveness analysis of colorectal cancer screening in Ireland. The recommendations of these evaluations were accepted by the National Immunisation Advisory Committee and the Minister for Health and Children and have been introduced as part of national policy. Dr. Tilson is an active participant in various international projects, including the European Network for HTA (EUnetHTA) and the Pharmaceutical Pricing and Reimbursement Information (PPRI) project. She is a member of the Scientific Advisory Group and the Programme Advisory Group of the HTA Directorate of the Health Information and Quality Authority in Ireland. In addition, Dr. Tilson is active in teaching Pharmacoeconomics at various workshops and on undergraduate and postgraduate courses.
Jalpa A. Doshi PhD
Jalpa A. Doshi PhD
Jalpa A. Doshi PhD is an Assistant Professor of Medicine at the University Of Pennsylvania School Of Medicine. She is also Director of Value-Based Insurance Design Initiatives at the Leonard Davis Institute of Health Economics Center for Health Incentives and Director of the Economic Evaluations Unit of the Center for Evidence-based Practice at the University of Pennsylvania Health System. Dr. Doshi's research interests involve economic and outcomes assessments of medication use and adherence in vulnerable patient populations such as the elderly, disabled, and chronically ill using observational as well as randomized trial data. Her work also examines prescription benefit designs and reimbursement policies and their impact on access to prescription drugs and biologics, and the quality and cost of health care. She has extensive experience conducting evaluations using Medicare (Part D), Medicaid, VA, and commercial insurance datasets in diverse disease areas such as cardiovascular and metabolic diseases, mental illnesses, rheumatoid arthritis and other inflammatory disorders. Dr. Doshi's research also focuses on methodological issues in cost-effectiveness analysis, and she has co-authored a book on Economic Evaluation in Clinical Trials (Oxford University Press). She teaches methodology courses and workshops on cost-effectiveness analyses in randomized trials, analytic techniques to estimate cost data, and statistical methods for dealing with confounding at ISPOR and several other scientific meetings. Dr. Doshi is currently Chair of the ISPOR Award for Excellence in Application of Pharmacoeconomics and Health Outcomes Research Task Force and Co-chair of the Health Technology Assessment (HTA) Principles Working Group of the ISPOR HTA Special Interest Group.
Anirban Basu PhD
Anirban Basu PhD
Anirban Basu (MS Biostatistics, UNC, Chapel Hill; PhD, Public Policy, University of Chicago) is an Assistant Professor of Medicine at the University of Chicago and is affiliated with the Chicago Center for Health and the Social Sciences and the University of Chicago Cancer Research Foundation. He is also a faculty research fellow at the National Bureau of Economic Research. Dr. Basu's research interests lie in revealing heterogeneity in clinical and economic outcomes in order to establish the value of individualized care and translating such information for public policy using innovative methods in comparative effectiveness and cost-effectiveness research. Dr. Basu has extensive experience in modeling health expenditure data and has also worked on the theoretical and empirical foundations in cost-effectiveness analyses and value of information analyses in the context of prostate cancer and schizophrenia. Some of his work include establishing the value of individualized care based on patient preferences, measuring the effect of patients' health on the quality of life of their partners, estimating the future value of research in Duchenne muscular dystrophy, developing simulation models for evaluating the cost-effectiveness of pharmacological treatment algorithms in schizophrenia, and comparative effectiveness research on the dynamic intensification of glucose lowering therapies in diabetes. Dr. Basu is an Associate Editor for both Health Economics and the Journal of Health Economics and co-teaches courses on decision analysis and cost-effectiveness analysis at the University of Chicago. Dr. Basu was the recipient of the 2007 ISPOR ISPOR Award for Excellence in Methodology in Pharmacoeconomics and Health Outcomes Research.
Patrick W. Sullivan PhD
Patrick W. Sullivan PhD
Patrick W. Sullivan PhD is an Assistant Professor at the University of Colorado Denver in the Pharmaceutical Outcomes Research Program. He received his PhD in Pharmaceutical Economics and Policy from the University of Southern California in 2001. Before joining USC, Dr. Sullivan worked for Merck & Co. from 1993 to 1998 and received his MA in Economics from the University of Colorado Denver in 1993. He has published widely on cost-effectiveness analysis, utility and preferences, pharmacoeconomics and patient reported outcomes. Dr. Sullivan recently completed an NIH/National Institute of Aging grant to develop a catalogue of utility scores for chronic conditions that can be used in cost-effectiveness analyses, resulting in a web-based utility calculator for chronic conditions, comorbidities and sociodemographic characteristics. In addition, Dr. Sullivan is active in teaching pharmacoeconomics and outcomes research to professional and graduate students.
Todd A. Lee, PharmD, PhD
Todd A. Lee, PharmD, PhD
Todd A. Lee, PharmD, PhD is currently a senior investigator in the Center for the Management of Complex Chronic Care (CMC3) at the Hines VA Hospital, which is one of 15 VA Centers of Excellence for health services research. He is also a research assistant professor in the Institute for Healthcare Studies and the Division of General Internal Medicine in the Northwestern University Feinberg School of Medicine. Dr. Lee's research focuses on patient outcomes related to the use of medications with interest in both safety related issues (pharmacoepidemiology) and costs associated with medication use (pharmacoeconomics) and the intersection of the two disciplines. He has conducted both observational and interventional projects across a variety of areas including COPD, asthma, diabetes, cancer, and mental illness with particular interest in understanding the impact of the co-occurrence of multiple chronic conditions. Dr. Lee earned his PharmD from Drake University and his Ph.D. from the Pharmaceutical Outcomes Research and Policy Program at the University of Washington.
Dr. John F P Bridges
Dr. John F P Bridges
Dr. John F P Bridges, is currently Group Leader, International Health Economics and Outcomes Research, University of Heidelberg-School of Medicine. Born and educated in Australia, John has spent his professional career in North America and Europe. In 2002 he graduated from the City University of New York, where he studied Health Economics under Professor Michael Grossman. In July 2002 he was appointed Assistant Professor in Health Services Research at Case Western Reserve University School of Medicine, Cleveland, USA. In July 2004 he moved to the University of Heidelberg to head a group of young researchers in "International Health Economics and Outcomes Research', In July 2006, Dr. Bridges will join the faculty at Johns Hopkins Bloomberg School of Public Health, where he will continue his research and international collaborations in outcomes research. Dr. Bridges' research is concentrated in four key areas. First, he has argued strongly for the inclusion of patient preferences (rather than utilities) in outcomes research and health technology assessment (HTA). Second he has studied the role that risk and uncertainty should play in decision making (including Cost-Effectiveness Analysis), using methods from finance theory such as portfolio analysis to demonstrate how risk could be measured and managed. Third, he has been concerned with the effects of HTA on innovation, especially given that some countries use HTA to delay market access. And fourth, he has applied econometric theory to the risk adjustment of adverse events with specific attention on the effects that organization and team characteristics have on the quality of care. Dr. Bridges is an active member of ISPOR and has made numerous presentations and presented posters at both the international and European meetings. He also serves on the editorial boards of PharmacoEconomics and Applied Health Economics and Health Policy.
Shelby D. Reed, Ph.D., RPh
Shelby D. Reed, Ph.D., RPh
Shelby D. Reed, Ph.D., RPh, is currently an Assistant Research Professor in the School of Medicine at Duke University in Durham, NC. Since 2000 Dr. Reed has been a faculty member in the Center for Clinical and Genetic Economics at the Duke Clinical Research Institute. Dr. Reed has a broad range of experience in planning and conducting economic and health outcome evaluations of pharmaceuticals and health care services across many different therapeutic areas including infectious diseases, oncology, dermatology, cardiovascular disease, and cerebrovascular disease. Her methodological interests include handling and representing uncertainty in economic evaluations, hierarchical modeling, and conducting and assessing the generalizability of economic evaluations performed alongside multinational clinical trials. Dr. Reed received her B.S. and Ph.D. from the University of Maryland School of Pharmacy and completed a two-year NIH post-doctoral fellowship at the University of Washington's Pharmaceutical Outcomes Research and Policy Program and the Center for AIDS and STDs.

Return to Awards Main Page